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Revolutionary Genome Sequencing
Technologies—The $1,000 Genome
The purpose of this Request for Applications
(RFA) is to solicit grant applications to develop
novel technologies that will enable extremely low-
cost genomic DNA sequencing. Current tech-
nologies are able to produce the sequence of a
mammalian-sized genome of the desired data
quality for $10–50 million; the goal of this initia-
tive is to reduce costs by at least four orders of
magnitude, so that a mammalian-sized genome
could be sequenced for approximately $1,000.
Substantial fundamental research is needed to
develop the scientific and technological knowl-
edge underpinning such a major advance.
Therefore, it is anticipated that the realization of
the goals of this RFA is a long-range effort that is
likely to require as much as ten years to achieve. A
parallel RFA HG-04-002 (http://grants.nih.gov/
grants/guide/rfa-files/RFA-HG-04-002.html)
solicits grant applications to develop technolo-
gies to meet the shorter-term goal of achieving
two-orders of magnitude cost reduction in about
ﬁve years.
The ability to sequence complete genomes
and the free dissemination of the sequence data
have dramatically changed the nature of biologi-
cal and biomedical research. Sequence and other
genomic data have the potential to lead to
remarkable improvement in many facets of
human life and society, including the under-
standing, diagnosis, treatment and prevention of
disease; advances in agriculture, environmental
science and remediation; and the understanding
of evolution and ecological systems.
The ability to sequence many genomes com-
pletely has been made possible by the enormous
reduction of the cost of sequencing in the past
two decades, from tens of dollars per base in the
1980s to a few cents per base today. However,
even at current prices, the cost of sequencing a
mammalian-sized genome is tens of millions of
dollars and, accordingly, we must still be very
selective when choosing new genomes to
sequence. In particular, we remain very far away
from being able to afford to use comprehensive
genomic sequence information in individual
health care. For this, and many other reasons, the
rationale for achieving the ability to sequence
entire genomes very inexpensively is very strong.
There are many areas of high priority
research to which genomic sequencing at dramat-
ically reduced cost would make vital contribu-
tions. 1) Expanded comparative genomic analysis
across species, which will yield great insights into
the structure and function of the human genome
and, consequently, the genetics of human health
and disease. Studies to date that have been able
to compare small regions of several genomes, and
“draft” versions of full genomes, have clearly
demonstrated the need for much more complete
data sets. While some of the needed data will be
obtained over the next two or three years using
existing DNA sequencing technology, and while
costs will continue their gradual decline, the cost
of current approaches to sequence acquisition
will continue to limit the amount of useful data
that can be produced. 2) Studies of human
genetic variation and the application of such
information to individual health care, which will
also require much cheaper sequencing technol-
ogy. Today, genetic variation must be assessed
by genotyping the relatively few known differ-
ences at a relatively small number of loci within
the human population. A richer and better char-
acterized catalog of such variable sites is being
generated to support more detailed and power-
ful analyses.
While these methods are, and will become
even more, powerful and likely to provide a sig-
nificant amount of important new information,
they are nevertheless only a surrogate for deter-
mining the full, contiguous sequence of individ-
ual human genomes, and are not as informative
as sequencing would be. For example, current
genotyping methods are likely to miss rare differ-
ences between people at any particular location
in the genome and have limited ability to deter-
mine long-range information (e.g., genomic
rearrangements). Therefore, new methods based
on complete genomic sequencing will be needed
to use genomic information for individual health
care in the most effective manner possible. 3)
While the genomes of a few agriculturally impor-
tant animals and plants have been sequenced, the
most informative studies will require compar-
isons between different individuals, different
domesticated breeds and several wild variants of
each species. 4) Sequence analysis of microbial
communities, many members of which cannot
be cultured, would provide a rich source of med-
ically and environmentally useful information.
And accurate, rapid sequencing may also be the
best approach to microbial monitoring of food
and the environment, including rapid detection
and mitigation of bioterrorism threats.
Given the broad utility and high importance
of dramatically reducing DNA sequencing costs,
the National Human Genome Research Institute
(NHGRI) is launching two parallel technology
development programs. The first has the objec-
tive of reducing the cost of producing a high
quality sequence of a mammalian-sized genome
by two orders of magnitude (see accompanying
RFA, HG-04-002). The goal of the second pro-
gram, described in this RFA, is the development
of technology to sequence a genome for a cost
that is reduced by four orders of magnitude. For
both programs, the cost targets are defined in
terms of a mammalian-sized genome, about 3
gigabases (Gb), with a target sequence quality
equivalent to, or better than, that of the mouse
assembly published in December 2002 [Nature
420:520 (2002)]. 
The ultimate goal of this program is to
obtain technologies that can produce assembled
sequence (i.e., de novo sequencing). However, an
accompanying shorter-term goal is to obtain
highly accurate sequence data at the single base
level, i.e., without assembly information, that
can be overlaid onto a reference sequence for the
same organism (i.e., re-sequencing). This could
be achieved, for example, with short reads that
have no substantial information linking them to
other reads. While the sequence product of this
kind of technology would lack some important
information, such as information about genomic
rearrangements, it would nevertheless potentially
be available more rapidly and produce data of
great value for certain uses in studying disease
etiology and in individualized medicine.
Therefore, both programs’ objectives include a
balanced portfolio of projects developing both de
novo and re-sequencing technologies.
State-of-the-art technology (i.e., ﬂuorescence
detection of dideoxynucleotide-terminated DNA
extension reactions resolved by capillary array
electrophoresis [CAE]) allows the determination
of sequence “read” segments approximately 1000
nucleotides long. If all of the DNA in a 2-3 Gb
genome were unique, it would be possible to
determine the sequence of the entire genome by
generating a sufﬁcient number (millions) of ran-
domly-overlapping thousand-base reads and
align them by overlaps. However, the human
and the majority of other interesting genomes
contain a substantial amount of repetitive DNA
(short [tens to thousands of nucleotides], nearly
or completely identical sequences present in mul-
tiple [tens to thousands of] copies). To cope with
the complexities of repetitive DNA elements and
to assemble the thousand-base reads in the cor-
rect long-range order across the genome, current
genomic sequencing methods involve a variety of
additional strategies, such as the sequencing of
both ends of cloned DNA fragments, use of
libraries of cloned fragments of different lengths,
incorporation of map information, achievement
of substantial redundancy (multiple reads of each
nucleotide from overlapping fragments) and
application of sophisticated assembly algorithms
to align and ﬁlter the read information.
The “gold standard” for genomic sequencing
is 99.99% accuracy (not more than one error per
10,000 nucleotides) with essentially no gaps
(http://www.genome.gov/10000923). At pre-
sent, the final steps in achieving that very high
sequence quality cannot be automated and
require substantial hand-crafting. However,
recent experience suggests that the majority of
comparative sequence information can be
obtained from automatically generated sequence
assemblies that have been variously identified as
“high-quality draft” or “comparative grade.”
Therefore, while the ultimate goal is sequencing
technology that produces perfect accuracy, the
goal of the current program is to develop tech-
nology for producing automatically generated
sequence of at least the quality of the mouse draft
genome sequence that was published in
December 2002 [Nature 420:520 (2002)].
Emerging technologies, collectively charac-
terized as sequencing-by-synthesis or sequencing-
by-extension, may be able to achieve large
numbers of sequence reads by extending very
large numbers of different DNA templates simul-
taneously, but generally only for a few tens of
bases as currently practiced. Even if it is possible
to extend these reads to several hundred bases, it
will still be necessary to link those reads to
achieve long-range sequence contiguity. For
some purposes, long-range sequence contiguity
may not be required. For example, the re-
sequencing of genomes (determination of the
DNA sequence for many individuals of a species
after a reference sequence for that species has
been determined), such as might be used for
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by aligning individual reads on the reference
sequence. However, short reads, particularly ones
with lower per-base quality, can be very difﬁcult
to align given the nature of repetitive DNA and
of closely-related gene families in complex
genomes. Also, chromosomal rearrangements
may be difficult to detect without high quality
sequence information bridging the breakpoints
with enough sequence to know in which repeat
the breakpoint lies. The determination of single
nucleotide polymorphisms (SNPs) and their
phase (for haplotypes) also requires contiguity of
varying length. The ultimate goal and a high pri-
ority for the NHGRI’s sequencing technology
development efforts, as exempliﬁed in these two
RFAs, continues to be de novo, assembled
sequence. However, because of the value of re-
sequencing for many future purposes, these RFAs
also solicit the development of very inexpensive
technology for very high quality re-sequencing
(without assembly).
Most investigators interested in reducing
DNA sequencing costs anticipate that a few
additional two-fold decreases in cost can yet
be achieved with the current CAE-based tech-
nology, with a realistic lower limit of perhaps
$5 million per mammalian-sized genome.
However, it is likely that this efﬁciency will only
be achieved in a few very large, well-capitalized,
experienced, automated laboratories. To achieve
the broadest beneﬁt from DNA sequencing tech-
nology for biology and medicine, systems that
are not only substantially more efﬁcient but also
more usable by the average research laboratory
are needed.
One set of current technology development
efforts is aimed at increasing parallel sample pro-
cessing while integrating the sample preparation
and analysis steps on a single platform. Thus, in
one approach, lithography is used to create a
large number of microchannels on a single device
and to integrate an efﬁcient sample injector with
each separation channel. Chambers for on-chip
DNA amplification, cycle sequencing reactions
and sample clean-up have been also developed,
and experiments to integrate these steps, an
approach that effectively places much of the
actual process and process control onto the
device, are being conducted in several laborato-
ries. Attendant improvements in separation poly-
mers and in fluorescent dyes will facilitate these
developments. As these approaches are based
largely on the experience of currently successful
high-throughput CAE-based methods, they have
potential to produce cost savings in the range of
several factors of two beyond the CAE-based sys-
tem itself. They also have the potential to widen
the user base for the technology, as the infra-
structure and knowledge needed to conduct rela-
tively high-throughput sequencing, or clinical
diagnostic sequencing, would be substantially
reduced and simpliﬁed.
Other approaches to improving sequencing
technology involve methods that are independent
of the Sanger dideoxynucleotide chain termina-
tion reaction or of electrophoretic separation of
the termination products. Two methods that were
proposed in the early days of the HGP involve the
use of mass spectrometry and sequencing by
hybridization. Both methods have been pursued,
with some limited success for sequencing, but sub-
stantial success for other types of DNA analysis.
Both continue to hold additional potential utility
for sequencing, although certain inherent limita-
tions will need to be overcome.
More recently, additional methodologies
have been investigated. These may be classified
into two approaches. One is sequencing-by-
extension, in which template DNA is elongated
stepwise and each extension product is detected.
Extension is generally achieved by the action of a
polymerase that adds a deoxynucleotide, fol-
lowed by detection of a fluorescent or chemilu-
minescent signal; the cycle is then repeated.
Modifications of this approach rely on other
types of enzymes and detection of hybridization
of labeled oligonucleotides. To obtain sufficient
throughput, the method is implemented at a
high level of multiplexing, e.g., by arraying large
numbers of sequencing extension reactions on a
surface. A key factor in this general approach is
the manner in which the fluorescent signal is
generated and the system requirements thus
imposed. Depending on the specific approach,
challenges of template extension methods include
the synthesis of labeled nucleotide analogues;
identiﬁcation of processive polymerases that can
incorporate nucleotide analogs with high ﬁdelity;
discrimination of fluorescent nucleotides that
have been incorporated into the growing chain
from those present in the reaction mix (back-
ground); distinction of subsequent nucleotide
additions from previous ones; accurate enumera-
tion of homopolymer runs (multiple sequential
occurrence of the same nucleotide); maintenance
of synchrony among the multiple copies of DNA
being extended to generate a detectable signal, or
achievement of sensitivity that detects extension
of individual DNA molecules; and development
of ﬂuidics, surface chemistry, and automation to
build and run the system. Current efforts to
develop such methods have produced, at best,
short sequence reads (less than or equal to 100
bases), so a continuing challenge is to extend
read length and develop sequence assembly
strategies. NHGRI anticipates that the state of
the art for this approach is sufﬁciently advanced
that, with additional investment, it may be possi-
ble to achieve proof of principle or even early
commercialization for genome-scale sequencing
within ﬁve years. It is anticipated that the cost of
genome sequencing with this technology could
be reduced by two orders of magnitude from
today’s costs. It is important to note that
sequencing by extension is one prototype for
achieving these time and cost goals, but other
technological approaches may also be viable.
Reaching this goal is the subject of a parallel
RFA, HG-04-002 (http://grants.nih.gov/
grants/guide/rfa-ﬁles/RFA-HG-04-002.html). 
A second alternative to CAE sequencing
seeks to read out the linear sequence of
nucleotides without copying the DNA and with-
out incorporating labels, relying instead on
extraction of signal from the native DNA
nucleotides themselves. The most familiar model
for this approach, but almost certainly not the
only way to achieve 10,000-fold reduction in
sequencing costs, is nanopore sequencing, first
introduced in the mid-1990s. Generally, this
approach requires a sensor, perhaps comparable
in size to the DNA molecule itself, that interacts
sequentially with individual nucleotides in a
DNA chain and distinguishes between them on
the basis of chemical, physical or electrical prop-
erties. Optimal implementation of such a
method would analyze intact, native genomic
DNA molecules isolated from biological, med-
ical or environmental samples without amplifi-
cation or modification, and would provide very
long sequence reads (tens of thousands to mil-
lions of bases) rapidly and at sufficiently high
redundancy to produce assembled sequence of
high quality. NHGRI anticipates that the sci-
ence and technology needed to reduce sequenc-
ing costs by four orders of magnitude, whether
by the nanopore or some other approach, will
require substantial basic research and develop-
ment, and may take as long as ten years to
achieve. Such a sustained research program is
the subject of this RFA.
The goal of research supported under this
RFA is to develop new, or improved technology
to enable rapid, efﬁcient genomic DNA sequenc-
ing. The specific goal is to reduce sequencing
costs by at least four orders of magnitude --
$1000 serves as a useful target cost for a mam-
malian-sized genome because the availability of
complete genomic sequences at that cost would
revolutionize biological research and medicine.
New sensing and detection modalities will likely
be needed to achieve these goals. New fabrication
technologies may also be required. It is therefore
anticipated that proposals responding to this
RFA will need to involve fundamental and engi-
neering research conducted by multidisciplinary
teams of investigators. The guidance for budget
requests accommodates the formation of groups
having investigators at several institutions, in
cases where that is needed to assemble a team of
the appropriate balance, breadth and experience.
The scientiﬁc and technical challenges inher-
ent in achieving a 10,000-fold reduction in
sequencing costs are clearly daunting. Achieving
this goal may require research projects that entail
substantial risk. That risk should be balanced by
an outstanding scientific and management plan
designed to achieve the very high payoff goals of
this solicitation.
Although the ultimate goal of this RFA is to
develop full-scale sequencing systems, indepen-
dent research on essential components will also
be considered to be responsive. However, it will
be important for applicants proposing research
on system components or concepts to describe
how the knowledge gained as a result of their
project would be incorporated into a full system
that they might subsequently propose to develop,
or that is being developed by other groups. Such
independent proposals are an important path for
pursuing novel, high risk/high pay-off ideas.
Research conducted under this RFA may
include development of the computational tools
associated with the technology, e.g., to extract
sequence information, including signal process-
ing, and to evaluate sequence quality and assign
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to assemble the sequence from the information
being obtained from the technology or by merg-
ing the sequence data with information from
parallel technology. However, this RFA will not
support development of sequence assembly soft-
ware independent of technology development to
obtain the sequence.
The quality of sequence to be generated by
the technology is of paramount importance for
this solicitation. Two major factors contributing
to genomic sequence quality are per-base accu-
racy and contiguity of the assembly. Much of the
utility of comparative sequence information will
derive from characterization of sequence varia-
tion between species, and between individuals of
a species. Therefore, per-base accuracy must be
high enough to distinguish polymorphism at the
single-nucleotide level (substitutions, insertions,
deletions). Experience and resulting policy have
established a target accuracy of not more than
one error per 10,000 bases. All applications in
response to this RFA, whether to develop re-
sequencing or de novo sequencing technologies,
must propose achieving per-base quality at least
to this standard.
Assembly information is needed for deter-
mining sequence of new genomes, and ultimately
also for genomes for which a reference sequence
exists, to detect rearrangements, insertions and
deletions. Rearrangements are known to cause
diseases; knowledge of rearrangement can reveal
new biological mechanisms. The phase of single
nucleotide polymorphisms to deﬁne haplotypes is
important in understanding and diagnosing dis-
ease. Achieving a high level of sequence contigu-
ity will be essential to achieve the full benefit
from the use of sequencing for individualized
medicine, e.g., to evaluate genomic contributions
to risk for specific diseases and syndromes, and
drug responsiveness. Nevertheless, it is recognized
that perfect sequence assembly from end to end
of each chromosome is unlikely to be achievable
with most technologies in a fully automated fash-
ion and without adding considerable cost.
Therefore, for the purpose of this solicitation,
grant applications proposing technology develop-
ment for de novo sequencing shall describe how
they will achieve, for about $1000, a draft-quality
assembly that is at least comparable to that repre-
sented by the mouse draft sequence produced by
December 2002: 7.7-fold coverage, 6.5-fold cov-
erage in Q20 bases, assembled into 225,000
sequence contigs connected by at least two read-
pair links into supercontigs [total of 7,418 super-
contigs at least 2 kb long], with N50 length for
contigs equal to 24.8 kb and for supercontigs
equal to 16.9 Mb [Nature 420:520 (2002)].
The grant applications will be evaluated, and
funding decisions made, in such a way as to
develop a balanced portfolio that has strong
potential to develop both robust re-sequencing
and de novo sequencing technologies. If the esti-
mate that achieving the goal of $1000 de novo
genome sequencing incorporating substantial
assembly information will require about 10 years
to achieve is correct, then re-sequencing tech-
nologies might be expected to be demonstrated
in a shorter time. Grant applications that present
a plan to achieve high quality re-sequencing
while on the path to high quality de novo
sequencing will receive high priority.
The major focus of this RFA is on the devel-
opment of new technologies for detection of
nucleotide sequence. However, any new technol-
ogy will eventually have to be effectively incorpo-
rated into the entire sequencing workflow,
starting with a biological sample and ending with
sequence data of the desired quality, and this
issue should be addressed. Given that sample
preparation requirements are a function of the
detection method and the sample detection
method affects the way in which output data are
handled, these aspects of the problem are clearly
relevant and should be addressed in an appropri-
ate timeframe. However, NHGRI is interested in
seeing that the most critical and highest-risk
aspects of the project, on which the rest of the
project is dependent, are addressed and proven as
early as possible.
Practical implementation issues related to
workflow and process control for efficient, high
quality, high-throughput DNA sequencing
should be considered early. Some technology
development groups lack practical experience in
high throughput sequencing, and in testing of
methods and instruments for robust, routine
operation. Applicants may therefore wish to
include such expertise as they develop their suite
of collaborations and capabilities.
The goal of this research is to develop tech-
nology to produce sequence from entire genomes.
It is conceivable that sequence from selected
important regions (e.g., all of the gene regions)
could be determined in the near future, using
more conventional technologies, at very low cost.
However, that is not the purpose of this initiative,
and grant applications that propose to meet the
cost targets by sequencing only selected regions of
a genome will be considered unresponsive.
This RFA will use NIH R21, R21/R33, R01
and P01 award mechanism(s). As an applicant
you will be solely responsible for planning,
directing, and executing the proposed project. 
Applicants may request an R01 or P01
(depending on the organization of the proposed
project) if sufficient preliminary data are avail-
able to support such an application. A fully inte-
grated management and research plan should use
the R01 mechanism. The P01 mechanism
should be used if multiple projects under differ-
ent leadership must proceed in parallel; however,
the issue of synergy in a multi-focal effort is of
great importance and must be addressed in the
application.
Applicants requiring support to demonstrate
feasibility may apply for either an R21 pilot/
exploratory project or an R21/R33 award, which
offers single submission and evaluation of both a
feasibility/pilot phase (R21) and an expanded
development phase (R33) in one application.
The R21/R33 should be used when both quanti-
tative milestones for the feasibility demonstra-
tion, and a research plan for the follow-on
research, can be presented. The transition from
the R21 award to the R33 award will be expe-
dited by administrative review. The R21 alone is
appropriate when the possible outcomes of the
proposed feasibility study are unclear and it is
not possible to propose sufﬁciently clear-cut and
quantitative milestones for administrative evalua-
tion, nor would it be possible to describe the
R33 phase of the research in sufficient detail to
allow adequate initial review.
This RFA uses just-in-time concepts. It also
uses the modular budgeting as well as the non-
modular budgeting formats (see http://grants.
nih.gov/grants/funding/modular/modular.htm).
Speciﬁcally, if you are submitting an application
with direct costs in each year of $250,000 or less,
use the modular budget format. Otherwise follow
the instructions for non-modular budget research
grant applications. This program does not require
cost sharing as deﬁned in the current NIH Grants
Policy Statement at http://grants.nih.gov/grants/
policy/nihgps_2001/part_i_1.htm. However,
cost-sharing is permitted as a component of insti-
tutional commitment.
Applications must be prepared using the
PHS 398 research grant application instructions
and forms (rev. 5/2001). Applications must have
a DUN and Bradstreet (D&B) Data Universal
Numbering System (DUNS) number as the
Universal Identifier when applying for federal
grants or cooperative agreements. The DUNS
number can be obtained by calling (866) 705-
5711 or through the web site at http://www.
dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of
the PHS 398 form. The PHS 398 document is
available at http://grants.nih.gov/grants/
funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo,
301-435-0714, e-mail: GrantsInfo@nih.gov.
The Center for Scientiﬁc Review (CSR) will
not accept any application in response to this
RFA that is essentially the same as one currently
pending initial review, unless the applicant with-
draws the pending application. However, when a
previously unfunded application, originally sub-
mitted as an investigator-initiated application, is
to be submitted in response to an RFA, it is to be
prepared as a NEW application. That is, the
application for the RFA must not include an
Introduction describing the changes and
improvements made, and the text must not be
marked to indicate the changes from the previ-
ous unfunded version of the application.
Letters of intent must be received by 14
September 2004. Applications are due by 14
October 2004. The earliest anticipated start date
is 1 June 2005.
Contact: Jeffery A. Schloss, Division of
Extramural Research, NHGRI, Bldg 31, Rm
B2B07, Bethesda, MD 20892-2033 USA, 301-
496-7531, fax: 301-480-2770, e-mail:
jeff_schloss@nih.gov.
Reference: RFA No. RFA-HG-04-003
Near-term Technology Development for
Genome Sequencing
The purpose of this Request for Applications
(RFA) is to solicit grant applications to develop
novel technologies that will substantially reduce
the cost of genomic DNA sequencing. Current
technologies are able to produce the sequence of
Fellowships, Grants, & Awards
A 420 VOLUME 112 | NUMBER 7 | May 2004 • Environmental Health Perspectivesa mammalian-sized genome of the desired data
quality for $10–50 million; the goal of this ini-
tiative is to reduce costs by at least two orders of
magnitude. It is anticipated that emerging tech-
nologies are sufficiently advanced that, with
additional investment, it may be possible to
achieve proof of principle or even early stage
commercialization for genome-scale sequencing
within five years. A parallel RFA HG-04-003
(http://grants.nih.gov/grants/guide/rfa-files/
RFA-HG-04-003.html) solicits grant applica-
tions to develop technologies to meet the longer-
term goal of achieving four-orders of magnitude
cost reduction in about ten years.
The ability to sequence complete genomes
and the free dissemination of the sequence data
have dramatically changed the nature of biologi-
cal and biomedical research. Sequence and other
genomic data have the potential to lead to
remarkable improvement in many facets of
human life and society, including the under-
standing, diagnosis, treatment and prevention of
disease; advances in agriculture, environmental
science and remediation; and the understanding
of evolution and ecological systems.
The ability to sequence many genomes com-
pletely has been made possible by the enormous
reduction of the cost of sequencing in the past
two decades, from tens of dollars per base in the
1980s to a few cents per base today. However,
even at current prices, the cost of sequencing a
mammalian-sized genome is tens of millions of
dollars and, accordingly, we must still be very
selective when choosing new genomes to
sequence. In particular, we remain very far away
from being able to afford to use comprehensive
genomic sequence information in individual
health care. For this, and many other reasons, the
rationale for achieving the ability to sequence
entire genomes very inexpensively is very strong.
There are many areas of high priority
research to which genomic sequencing at dramat-
ically reduced cost would make vital contribu-
tions. 1) Expanded comparative genomic analysis
across species, which will yield great insights into
the structure and function of the human genome
and, consequently, the genetics of human health
and disease. Studies to date that have been able to
compare small regions of several genomes, and
“draft” versions of full genomes, have clearly
demonstrated the need for much more complete
data sets. While some of the needed data will be
obtained over the next two or three years using
existing DNA sequencing technology, and while
costs will continue their gradual decline, the cost
of current approaches to sequence acquisition will
continue to limit the amount of useful data that
can be produced. 2) Studies of human genetic
variation and the application of such information
to individual health care, which will also require
much cheaper sequencing technology. Today,
genetic variation must be assessed by genotyping
the relatively few known differences at a relatively
small number of loci within the human popula-
tion. A richer and better characterized catalog of
such variable sites is being generated to support
more detailed and powerful analyses.
While these methods are, and will become
even more, powerful and likely to provide a
significant amount of important new informa-
tion, they are nevertheless only a surrogate for
determining the full, contiguous sequence of
individual human genomes, and are not as infor-
mative as sequencing would be. For example,
current genotyping methods are likely to miss
rare differences between people at any particular
location in the genome and have limited ability
to determine long-range information (e.g.,
genomic rearrangements). Therefore, new meth-
ods based on complete genomic sequencing will
be needed to use genomic information for indi-
vidual health care in the most effective manner
possible. 3) While the genomes of a few agricul-
turally important animals and plants have been
sequenced, the most informative studies will
require comparisons between different individu-
als, different domesticated breeds and several
wild variants of each species. 4) Sequence analy-
sis of microbial communities, many members of
which cannot be cultured, would provide a rich
source of medically and environmentally useful
information. And accurate, rapid sequencing
may also be the best approach to microbial
monitoring of food and the environment,
including rapid detection and mitigation of
bioterrorism threats.
Given the broad utility and high importance
of dramatically reducing DNA sequencing costs,
NHGRI is launching two parallel technology
development programs. The first, described in
this RFA, has the objective of reducing the cost
of producing a high quality sequence of a mam-
malian-sized genome by two orders of magni-
tude. The goal of the second program (see
accompanying RFA HG-04-003) is the develop-
ment of technology to sequence a genome for a
cost that is reduced by four orders of magnitude.
For both programs, the cost targets are deﬁned in
terms of a mammalian-sized genome, about 3
gigabases (Gb), with a target sequence quality
equivalent to, or better than, that of the mouse
assembly published in December 2002 [Nature
420:520 (2002)]. 
The ultimate goal of this program is to
obtain technologies that can produce assembled
sequence (i.e., de novo sequencing). However, an
accompanying shorter-term goal is to obtain
highly accurate sequence data at the single base
level, i.e., without assembly information, that can
be overlaid onto a reference sequence for the same
organism (i.e., re-sequencing). This could be
achieved, for example, with short reads that have
no substantial information linking them to other
reads. While the sequence product of this kind of
technology would lack some important informa-
tion, such as information about genomic
rearrangements, it would nevertheless potentially
be available more rapidly and produce data of
great value for certain uses in studying disease eti-
ology and pharmacogenomics, and for compara-
tive genomics between closely-related organisms.
Therefore, both programs’ objectives include a
balanced portfolio of projects developing both de
novo and re-sequencing technologies. 
State-of-the-art technology (i.e., ﬂuorescence
detection of dideoxynucleotide-terminated DNA
extension reactions resolved by capillary array
electrophoresis [CAE]) allows the determination
of sequence “read” segments approximately 1000
nucleotides long. If all of the DNA in a 2-3 Gb
genome were unique, it would be possible to
determine the sequence of the entire genome by
generating a sufﬁcient number (millions) of ran-
domly-overlapping thousand-base reads and
align them by overlaps. However, the human
and the majority of other interesting genomes
contain a substantial amount of repetitive DNA
(short [tens to thousands of nucleotides], nearly
or completely identical sequences present in mul-
tiple [tens to thousands of] copies). To cope with
the complexities of repetitive DNA elements and
to assemble the thousand-base reads in the cor-
rect long-range order across the genome, current
genomic sequencing methods involve a variety of
additional strategies, such as the sequencing of
both ends of cloned DNA fragments, use of
libraries of cloned fragments of different lengths,
incorporation of map information, achievement
of substantial redundancy (multiple reads of each
nucleotide from overlapping fragments) and
application of sophisticated assembly algorithms
to align and ﬁlter the read information.
The “gold standard” for genomic sequencing
is 99.99% accuracy (not more than one error per
10,000 nucleotides) with essentially no gaps
(http://www.genome.gov/10000923). At pre-
sent, the final steps in achieving that very high
sequence quality cannot be automated and
require substantial hand-crafting. However,
recent experience suggests that the majority of
comparative sequence information can be
obtained from automatically generated sequence
assemblies that have been variously identified as
“high-quality draft” or “comparative grade.”
Therefore, while the ultimate goal is sequencing
technology that produces perfect accuracy, the
goal of the current program is to develop tech-
nology for producing automatically generated
sequence of at least the quality of the mouse draft
genome sequence that was published in
December 2002 [Nature 420:520 (2002)].
Emerging technologies, collectively charac-
terized as sequencing-by-synthesis or sequencing-
by-extension, may be able to achieve large
numbers of sequence reads by extending very
large numbers of different DNA templates simul-
taneously, but generally only for a few tens of
bases as currently practiced. Even if it is possible
to extend these reads to several hundred bases, it
will still be necessary to link those reads to
achieve long-range sequence contiguity. For
some purposes, long-range sequence contiguity
may not be required. For example, the re-
sequencing of genomes (determination of the
DNA sequence for many individuals of a species
after a reference sequence for that species has
been determined), such as might be used for
medical diagnostic purposes, could be achieved
by aligning individual reads on the reference
sequence. However, short reads, particularly ones
with lower per-base quality, can be very difﬁcult
to align given the nature of repetitive DNA and
of closely-related gene families in complex
genomes. Also, chromosomal rearrangements
may be difficult to detect without high quality
sequence information bridging the breakpoints
with enough sequence to know in which repeat
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nucleotide polymorphisms (SNPs) and their
phase (for haplotypes) also requires contiguity of
varying length. The ultimate goal and a high pri-
ority for the National Human Genome Research
Institute’s (NHGRI) sequencing technology
development efforts, as exempliﬁed in these two
RFAs, continues to be de novo, assembled
sequence. However, because of the value of re-
sequencing for many future purposes, these RFAs
also solicit the development of very inexpensive
technology for very high quality re-sequencing
(without assembly).
Most investigators interested in reducing
DNA sequencing costs anticipate that a few addi-
tional two-fold decreases in cost can yet be
achieved with the current CAE-based technology,
with a realistic lower limit of perhaps $5 million
per mammalian-sized genome. However, it is
likely that this efficiency will only be achieved
in a few very large, well-capitalized, experi-
enced, automated laboratories. To achieve the
broadest benefit from DNA sequencing tech-
nology for biology and medicine, systems that
are not only substantially more efficient but also
more usable by the average research laboratory
are needed.
One set of current technology development
efforts is aimed at increasing parallel sample pro-
cessing while integrating the sample preparation
and analysis steps on a single platform. Thus, in
one approach, lithography is used to create a
large number of microchannels on a single device
and to integrate an efﬁcient sample injector with
each separation channel. Chambers for on-chip
DNA amplification, cycle sequencing reactions
and sample clean-up have been also developed,
and experiments to integrate these steps, an
approach that effectively places much of the
actual process and process control onto the
device, are being conducted in several laborato-
ries. Attendant improvements in separation poly-
mers and in fluorescent dyes will facilitate these
developments. As these approaches are based
largely on the experience of currently successful
high-throughput CAE-based methods, they have
potential to produce cost savings in the range of
several factors of two beyond the CAE-based sys-
tem itself. They also have the potential to widen
the user base for the technology, as the infra-
structure and knowledge needed to conduct rela-
tively high-throughput sequencing, or clinical
diagnostic sequencing, would be substantially
reduced and simpliﬁed.
Other approaches to improving sequencing
technology involve methods that are independent
of the Sanger dideoxynucleotide chain termina-
tion reaction or of electrophoretic separation of
the termination products. Two methods that were
proposed in the early days of the HGP involve the
use of mass spectrometry and sequencing by
hybridization. Both methods have been pursued,
with some limited success for sequencing, but sub-
stantial success for other types of DNA analysis.
Both continue to hold additional potential utility
for sequencing, although certain inherent limita-
tions will need to be overcome.
More recently, additional methodologies
have been investigated. These may be classified
into two approaches. One is sequencing-by-
extension, in which template DNA is elongated
stepwise and each extension product is detected.
Extension is generally achieved by the action of a
polymerase that adds a deoxynucleotide, fol-
lowed by detection of a fluorescent or chemilu-
minescent signal; the cycle is then repeated.
Modifications of this approach rely on other
types of enzymes and detection of hybridization
of labeled oligonucleotides. To obtain sufficient
throughput, the method is implemented at a
high level of multiplexing, e.g., by arraying large
numbers of sequencing extension reactions on a
surface. A key factor in this general approach is
the manner in which the fluorescent signal is
generated and the system requirements thus
imposed. Depending on the specific approach,
challenges of template extension methods include
the synthesis of labeled nucleotide analogues;
identiﬁcation of processive polymerases that can
incorporate nucleotide analogs with high ﬁdelity;
discrimination of fluorescent nucleotides that
have been incorporated into the growing chain
from those present in the reaction mix (back-
ground); distinction of subsequent nucleotide
additions from previous ones; accurate enumera-
tion of homopolymer runs (multiple sequential
occurrence of the same nucleotide); maintenance
of synchrony among the multiple copies of DNA
being extended to generate a detectable signal, or
achievement of sensitivity that detects extension
of individual DNA molecules; and development
of ﬂuidics, surface chemistry, and automation to
build and run the system. Current efforts to
develop such methods have produced, at best,
short sequence reads (less than or equal to 100
bases), so a continuing challenge is to extend
read length and develop sequence assembly
strategies. NHGRI anticipates that the state of
the art for this approach is sufﬁciently advanced
that, with additional investment, it may be possi-
ble to achieve proof of principle or even early
commercialization for genome-scale sequencing
within ﬁve years. It is anticipated that the cost of
genome sequencing with this technology could
be reduced by two orders of magnitude from
today’s costs. It is important to note that
sequencing by extension is one prototype for
achieving these time and cost goals, but other
technological approaches may also be viable.
Developing technology with which to reduce the
cost of genome sequencing by 100-fold is the
subject of this RFA.
A second alternative to CAE sequencing
seeks to read out the linear sequence of
nucleotides without copying the DNA and with-
out incorporating labels, relying instead on
extraction of signal from the native DNA
nucleotides themselves. The most familiar model
for this approach, but almost certainly not the
only way to achieve 10,000-fold reduction in
sequencing costs, is nanopore sequencing, first
introduced in the mid-1990s. Generally, this
approach requires a sensor, perhaps comparable
in size to the DNA molecule itself, that interacts
sequentially with individual nucleotides in a
DNA chain and distinguishes between them on
the basis of chemical, physical or electrical prop-
erties. Optimal implementation of such a
method would analyze intact, native genomic
DNA molecules isolated from biological, medical
or environmental samples without amplification
or modification, and would provide very long
sequence reads (tens of thousands to millions of
bases) rapidly and at sufficiently high redun-
dancy to produce assembled sequence of high
quality. NHGRI anticipates that the science and
technology needed to reduce sequencing costs by
four orders of magnitude, whether by the
nanopore or some other approach, will require
substantial basic research and development, and
may take as long as ten years to achieve.
Reaching this goal is the subject of a parallel
RFA, HG-04-003 (http://grants.nih.gov/
grants/guide/rfa-ﬁles/RFA-HG-04-003.html).
The goal of research supported under this
RFA is to develop or improve technology to
enable rapid, efﬁcient genomic DNA sequencing.
The speciﬁc goal is to reduce sequencing costs by
at least two orders of magnitude—$100,000
serves as a useful target cost for a mammalian-
sized genome because the availability of complete
genomic sequences at that cost would revolution-
ize biological research and medicine. While not
in a cost range that would enable the use of
sequencing in individualized medicine, such
technology would permit the sequencing of
many genomes for a small fraction of current
costs. A 100-fold cost reduction would make
possible extensive studies of human variation for
disease gene studies, substantially expanded com-
parative genomics to understand the human
genome, and many other studies relevant to the
National Institutes of Health (NIH), other fed-
eral agencies and the private sector. Entirely new
lines of investigation would be enabled by mak-
ing “large-scale sequencing” accessible to the
diverse interests of many research laboratories
and companies.
Many projects aimed at next-generation
DNA sequencing technologies require substantial
advances in a combination of ﬁelds such as signal
detection, enzymology, chemistry, engineering,
bioinformatics, etc. It is therefore anticipated
that research programs responding to this RFA
will involve multidisciplinary teams of investiga-
tors. The guidance for budget requests accom-
modates the formation of groups having
investigators at several institutions, in cases
where that is needed to assemble a team of the
appropriate balance, breadth and experience.
The scientiﬁc and technical challenges inher-
ent in achieving a 100-fold reduction in sequenc-
ing costs are considerable. Achieving this goal
may require research projects that entail substan-
tial risk. That risk should be balanced by an out-
standing scientific and management plan
designed to achieve the very high payoff goals of
this solicitation.
Although the ultimate goal of this RFA is to
develop full-scale sequencing systems, indepen-
dent research on essential components will also
be considered to be responsive. However, it will
be important for applicants proposing research
on system components or concepts to describe
how the knowledge gained as a result of their
project would be incorporated into a full system
that they might subsequently propose to develop,
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independent proposals are an important path for
pursuing novel, high risk/high pay-off ideas.
Research conducted under this RFA may
include development of the computational tools
associated with the technology, e.g., to extract
sequence information, including signal process-
ing, and to evaluate sequence quality and assign
confidence scores. It may also address strategies
to assemble the sequence from the information
being obtained from the technology or by merg-
ing the sequence data with information from
parallel technology. However, this RFA will not
support development of sequence assembly soft-
ware independent of technology development to
obtain the sequence.
The quality of sequence to be generated by
the technology is of paramount importance for
this solicitation. Two major factors contributing
to genomic sequence quality are per-base accu-
racy and contiguity of the assembly. Much of the
utility of comparative sequence information will
derive from characterization of sequence varia-
tion between species, and between individuals of
a species. Therefore, per-base accuracy must be
high enough to distinguish polymorphism at the
single-nucleotide level (substitutions, insertions,
deletions). Experience and resulting policy have
established a target accuracy of not more than
one error per 10,000 bases. All applications in
response to this RFA, whether to develop re-
sequencing or de novo sequencing technologies,
must propose achieving per-base quality at least
to this standard.
Assembly information is needed for deter-
mining sequence of new genomes, and ultimately
also for genomes for which a reference sequence
exists, to detect rearrangements, insertions and
deletions. Rearrangements are known to cause
diseases; knowledge of rearrangement can reveal
new biological mechanisms. The phase of single
nucleotide polymorphisms to define haplotypes
is important in understanding and diagnosing
disease. Achieving a high level of sequence conti-
guity will be essential to achieve the full benefit
from the use of sequencing for individualized
medicine, e.g., to evaluate genomic contributions
to risk for specific diseases and syndromes, and
drug responsiveness. Nevertheless, it is recog-
nized that perfect sequence assembly from end to
end of each chromosome is unlikely to be achiev-
able with most technologies in a fully automated
fashion and without adding considerable cost.
Therefore, for the purpose of this solicita-
tion, grant applications proposing technology
development for de novo sequencing shall
describe how they will achieve, for about $1000,
a draft-quality assembly that is at least compara-
ble to that represented by the mouse draft
sequence produced by December 2002: 7.7-fold
coverage, 6.5-fold coverage in Q20 bases, assem-
bled into 225,000 sequence contigs connected by
at least two read-pair links into supercontigs
[total of 7,418 supercontigs at least 2 kb long],
with N50 length for contigs equal to 24.8 kb and
for supercontigs equal to 16.9 Mb [Nature
420:520 (2002)].
The grant applications will be evaluated,
and funding decisions made, in such a way as to
develop a balanced portfolio that has strong
potential to develop both robust re-sequencing
and de novo sequencing technologies. If the esti-
mate that achieving the goal of 100-fold reduc-
tion in cost for genome sequencing
incorporating substantial assembly information
will require about 5 years to achieve is correct,
then re-sequencing technologies might be
expected to be demonstrated in a shorter time.
Grant applications that present a plan to
achieve high quality re-sequencing while on the
path to high quality de novo sequencing will
receive high priority.
The major focus of this RFA is on the devel-
opment of new technologies for detection of
nucleotide sequence. However, any new technol-
ogy will eventually have to be effectively incorpo-
rated into the entire sequencing workflow,
starting with a biological sample and ending with
sequence data of the desired quality, and this
issue should be addressed. Given that sample
preparation requirements are a function of the
detection method and the sample detection
method affects the way in which output data are
handled, these aspects of the problem are clearly
relevant and should be addressed in an appropri-
ate timeframe. However, NHGRI is interested in
seeing that the most critical and highest-risk
aspects of the project, on which the rest of the
project is dependent, are addressed and proven as
early as possible.
NHGRI anticipates that successful projects
funded through this RFA may be sufficiently
advanced as to be approaching early stages of
commercialization within about five years.
Therefore, practical implementation issues
related to workﬂow and process control for efﬁ-
cient, high quality, high-throughput DNA
sequencing should be considered early. Some
technology development groups lack practical
experience in high throughput sequencing, and
in testing of methods and instruments for robust,
routine operation. Applicants may therefore wish
to include such expertise as they develop their
suite of collaborations and capabilities.
The goal of this research is to develop tech-
nology to produce sequence from entire
genomes. It is conceivable that sequence from
selected important regions (e.g., all of the gene
regions) could be determined in the near future,
using more conventional technologies, at very
low cost. However, that is not the purpose of
this initiative, and grant applications that pro-
pose to meet the cost targets by sequencing only
selected regions of a genome will be considered
unresponsive.
This RFA will use NIH R21, R21/R33, R01
and P01 award mechanism(s). As an applicant
you will be solely responsible for planning,
directing, and executing the proposed project.
Applicants may request an R01 or P01
(depending on the organization of the proposed
project) if sufficient preliminary data are avail-
able to support such an application. A fully inte-
grated management and research plan should use
the R01 mechanism. The P01 mechanism
should be used if multiple projects under differ-
ent leadership must proceed in parallel; however,
the issue of synergy in a multi-focal effort is of
great importance and must be addressed in the
application.
Applicants requiring support to demonstrate
feasibility may apply for either an R21
pilot/exploratory project or an R21/R33 award,
which offers single submission and evaluation of
both a feasibility/pilot phase (R21) and an
expanded development phase (R33) in one appli-
cation. The R21/R33 should be used when both
quantitative milestones for the feasibility demon-
stration, and a research plan for the follow-on
research, can be presented. The transition from
the R21 award to the R33 award will be expe-
dited by administrative review. The R21 alone is
appropriate when the possible outcomes of the
proposed feasibility study are unclear and it is
not possible to propose sufﬁciently clear-cut and
quantitative milestones for administrative evalua-
tion, nor would it be possible to describe the
R33 phase of the research in sufficient detail to
allow adequate initial review. 
This RFA uses just-in-time concepts. It also
uses the modular budgeting as well as the non-
modular budgeting formats (see http://grants.
nih.gov/grants/funding/modular/modular.htm).
Speciﬁcally, if you are submitting an application
with direct costs in each year of $250,000 or less,
use the modular budget format. Otherwise follow
the instructions for non-modular budget research
grant applications. This program does not require
cost sharing as deﬁned in the current NIH Grants
Policy Statement at http://grants.nih.gov/
grants/policy/nihgps_2001/part_i_1.htm.
However, cost-sharing is permitted as a compo-
nent of institutional commitment.
Applications must be prepared using the
PHS 398 research grant application instructions
and forms (rev. 5/2001). Applications must have
a DUN and Bradstreet (D&B) Data Universal
Numbering System (DUNS) number as the
Universal Identifier when applying for Federal
grants or cooperative agreements. The DUNS
number can be obtained by calling (866) 705-
5711 or through the web site at http://www.
dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of
the PHS 398 form. The PHS 398 document is
available at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format. For
further assistance contact GrantsInfo, 301-435-
0714, e-mail: GrantsInfo@nih.gov.
The Center for Scientiﬁc Review (CSR) will
not accept any application in response to this
RFA that is essentially the same as one currently
pending initial review, unless the applicant with-
draws the pending application. However, when a
previously unfunded application, originally sub-
mitted as an investigator-initiated application, is
to be submitted in response to an RFA, it is to be
prepared as a NEW application. That is, the
application for the RFA must not include an
Introduction describing the changes and
improvements made, and the text must not be
marked to indicate the changes from the previ-
ous unfunded version of the application.
Letters of intent must be received by
14 September 2004. Applications are due
14 October 2004. The earliest anticipated start
date: 1 June 2005.
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Extramural Research, NHGRI, Bldg 31, Rm
B2B07, Bethesda, MD 20892-2033 USA,
301-496-7531, fax: 301-480-2770, e-mail:
jeff_schloss@nih.gov.
Reference: RFA No. RFA-HG-04-003
In Vivo Cellular and Molecular Imaging
Centers (ICMICS)
The Cancer Imaging Program, Division of Cancer
Diagnosis and Treatment of the National Cancer
Institute (NCI), invites applications for new or
competing P50 Research Center Grants for In
vivo Cellular and Molecular Imaging Centers
(ICMICs). This initiative is designed to capitalize
on the extraordinary opportunity for molecular
imaging to have an impact on the diagnosis and
treatment of cancer patients non-invasively and
quantitatively. Molecular imaging technologies
can provide valuable laboratory tools for the inter-
rogation of biological pathways relevant to cancer,
as well as to provide imaging agents and technolo-
gies that will be directly utilized in the clinic. The
five-year P50 ICMIC grants described in this
PAR are designed to bring together interdiscipli-
nary scientiﬁc teams to lead the nation in cutting-
edge cancer molecular imaging research with
clinical relevance, provide unique core facilities to
support oncology imaging research, provide ﬂexi-
bility to respond to exciting pilot research oppor-
tunities, and provide interdisciplinary career
development opportunities for investigators new
to the ﬁeld of molecular cancer imaging. The P50
mechanism will promote coordination, interrela-
tionships and scientific synergy among the
research components and resources, leading to a
highly integrated imaging center.
The ﬁeld of molecular imaging has made sig-
niﬁcant advances in recent years. The formation
of multidisciplinary research teams has stimu-
lated and streamlined cancer imaging research
from inception to use in patient care. The P50
ICMIC structure allows mechanistic flexibility
for each Institution to capitalize on its own
unique scientific strengths, and to define the
structure and research objectives that create the
most synergistic and creative scientific interac-
tions. In general, an ICMIC will provide
researchers with the following critical resources:
The ICMICs will provide an organizational
structure speciﬁcally designed to facilitate multi-
disciplinary interactions among investigators
focused on the ultimate goal of discovering,
developing and translating molecular imaging
technologies that will have eventual impact in
the clinic. This structure will provide researchers
with access to a concentrated pool of expertise in
a wide range of disciplines. The structure of the
ICMIC will be designed to provide investigators
with the means of conducting multidisciplinary
research in a highly collaborative atmosphere,
and consistent access to expertise with minimal
wasted time and effort. Personnel may be scien-
tists from a variety of fields including, but not
limited to: imaging sciences, chemistry, radio-
pharmaceutical chemistry, cell and molecular
biology, pathology, pharmacology, computa-
tional sciences, and biomedical engineering.
Other specialists in fields such as MRI physics,
immunology, or neuroscience, for example, may
also be involved. Most importantly, ICMIC per-
sonnel must demonstrate an eagerness to collabo-
rate outside of their own disciplines. The nature
of these interactions will be determined by the
applicants, and emphasis will be placed on estab-
lishing creative, productive, and synergistic inter-
actions with eventual clinical impact.
The ICMICs will provide funding for a min-
imum of three Research Components. Research
Components will apply multidisciplinary
approaches to molecular imaging. Individual
research projects will be structured in order to
maximize appropriate scientific interaction
between the projects, and coordinated utilization
of the Specialized Resources (see below). Each
Research Component will be similar in size and
scope to a typical R01 or subproject of a P01, and
will be expected to meet the same standards of
preliminary data in support of the hypotheses.
The ICMICs will provide Specialized
Resource Facilities and Services. A barrier to pro-
ductive scientific interaction is the lack of avail-
able facilities for cross-disciplinary experiments.
Demands on equipment, resources, and reagents
in every scientific area are extremely high, and
this demand prohibits ready access to investiga-
tors interested in expanding their studies into new
areas of research. The establishment of Special-
ized Resources dedicated to ICMIC-related
research will provide this access. The Specialized
Resource(s) will be determined by the require-
ments of the Institution, the defined scientific
goals of the Research Components of the
ICMIC, and budgetary limits. Prioritization of
the research projects supported through ICMIC
Specialized Resources will be an essential function
of the ICMIC’s leadership, and the mechanism to
be employed for prioritization must be delineated
by the applicants. Resource facilities may be uti-
lized by active members of the ICMIC and will
also be available to investigators supported
through Developmental Funds (see below).
ICMICs will provide Developmental Funds
for feasibility testing of new projects. A high pri-
ority of each ICMIC will be the identification
and support of pilot projects that identify and
stimulate interdisciplinary projects that will take
full advantage of emerging research opportunities.
The selection of projects will be through a review
process established by the ICMIC’s leadership.
The portfolio of ongoing projects in any given
Program is expected to be extremely dynamic.
This fund is not to be used to support traditional,
ongoing projects that could readily be supported
through R01s. It is not appropriate for projects
that utilize single areas of expertise or to support
the continuation of previously funded research
projects, and Developmental Projects may not be
supported for more than two years. Necessary
equipment should be provided through the
appropriate Specialized Resource. These projects
are to be monitored closely by the ICMIC leader-
ship. Investigators working on projects supported
through the Development Fund must understand
that they will be expected to compete for inde-
pendent R01 funding when the projects become
sufficiently mature. Alternatively, if it becomes
obvious that the project will not provide the
expected results, a plan should be in place for ter-
minating a development project.
ICMICs will provide career development
opportunities for new and established investiga-
tors. Current graduate programs are generally
focused on single disciplines and may be inade-
quate to train the needed cadre of inter-discipli-
nary imaging scientists. The ICMICs will
provide support for a limited number of pre-and
post-doctoral trainees in a program to be deﬁned
by the applicants. Career development opportu-
nities through the ICMIC will be expected to be
highly cross-disciplinary.
This PAR will use the NIH P50 Specialized
Centers Grant Mechanism. As an applicant, you
will be solely responsible for planning, directing,
and executing the proposed project. The total
project period for a P50 application submitted in
response to this PAR may not exceed five years.
The total costs requested for a new or competing
renewal P50 ICMIC application may not exceed
a maximum of $2,000,000 per year. The NCI
anticipates awarding two new or competing P50
ICMICs each year.
This PAR uses just-in-time concepts. It also
uses the non-modular budgeting formats. Follow
the instructions for non-modular budget research
grant applications. This program does not require
cost sharing as deﬁned in the current NIH Grants
Policy Statement at http://grants.nih.gov/
grants/policy/nihgps_2003/NIHGPS_Part2.
htm#Toc54600040.
Applications must be prepared using the PHS
398 research grant application instructions and
forms (rev. 5/2001). Applications must have a
Dun and Bradstreet (D&B) Data Universal
Numbering System (DUNS) number as the
Universal Identifier when applying for federal
grants or cooperative agreements. The DUNS
number can be obtained by calling (866) 705-
5711 or through the web site at http://www.
dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of
the PHS 398 form. The PHS 398 document is
available at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format. For
further assistance contact GrantsInfo, 301-435-
0714, e-mail: GrantsInfo@nih.gov.
Applications hand-delivered by individuals to
the NCI will no longer be accepted. This policy
does not apply to courier deliveries (i.e. FEDEX,
UPS, DHL, etc.) See http://grants.nih.gov/
grants/guide/notice-files/NOT-CA-02-002.html
for more information. This policy is similar to
and consistent with the policy for applications
addressed to Centers for Scientific Review as
published in the NIH Guide Notice at http://
grants.nih.gov/grants/guide/notice-files/
NOT-OD-02-012.html.
Applications must be received on or before
the receipt date(s) listed on the ﬁrst page of this
PA. The CSR will not accept any application in
response to this PAR that is essentially the same
as one currently pending initial review unless the
applicant withdraws the pending application.
The CSR will not accept any application that is
essentially the same as one already reviewed. This
does not preclude the submission of a substantial
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already reviewed, but such application must
include an Introduction addressing the previous
critique. 398 research grant application instruc-
tions (rev. 5/2001) will be assessed. 
Letters of intent must be received by 22 June
2004 and 21 June 2005. Applications must be
received by 22 July 2004 and 21 July 2005. The
earliest anticipated start dates are April 2005 and
April 2006.
Contact: Anne E. Menkens, Cancer Imaging
Program, NCI, 6130 Executive Blvd, EPN Rm
6068, Bethesda, MD 20892-8329 USA,
(Rockville, MD 20852 for express/courier ser-
vice), 301-496-9531, fax: 301-480-3507, e-mail:
am187k@nih.gov.
Reference: PA No. PAR-04-069
Pharmacogenetics Research Network and
Knowledge Base
The purpose of this RFA is to solicit applica-
tions for an open re-competition of the
Pharmacogenetics Research Network and
Knowledge Base (http://www.nigms.nih.gov/
pharmacogenetics). This is a network of multidis-
ciplinary, collaborative groups of investigators
that contribute their data to the publicly available
knowledge base PharmGKB, which is an open
research tool accessible to all scientists.
The research groups in the network have
interests across a range of biological processes:
drug metabolism, small molecule transport, tar-
get receptors, and biological pathways involved
in the drug treatment of cardiovascular diseases,
asthma, cancer, and depression; other areas are
welcome consistent with the interests of the
funding institutes. The groups are collecting
comprehensive, integrative information about
specific proteins and gene families important to
the field of pharmacogenetics. Some groups are
using a genotype-to-phenotype approach starting
with the detection of all possible variants, while
other groups are employing a phenotype-to-
genotype approach beginning with well-charac-
terized clinical samples. All investigations are
converging on the association of single
nucleotide polymorphisms (SNPs) and haplo-
types with drug responses. The results are con-
ﬁrmed by studies of the mechanistic and clinical
consequences of the molecular changes. The
database groups in the network are working
towards the goal of creating a centralized public
knowledge base. PharmGKB (http://www.
pharmgkb.org) is designed to categorize four
types of phenotype information—functional
assays, pharmacokinetics, pharmacodynamics,
and clinical outcomes—correlated with genotype
information. The knowledge base uses standard-
ized drug, disease, and genetic vocabularies and is
linked to existing databases. 
The plans are to continue funding this net-
work as a series of cooperative groups conducting
studies to address a wide variety of common
research problems in pharmacogenetics. This ini-
tiative will further emphasize development of the
PharmGKB knowledge base; it is envisioned as
an information resource that will be useful to the
entire pharmacogenetics research community to
enable future hypothesis-driven research. This
competition is open to both new and renewal
research and database groups.
Pharmacogenetics can be deﬁned as the inﬂu-
ence of human genetic variation on drug
responses. It has long been known from family
studies that variations found in enzymes of drug
clearance have profound effects on the efﬁcacy and
duration of drug action, sometimes with signifi-
cant adverse consequences. Genetic variations in
drug metabolizing enzymes can lead to the exces-
sive build-up of a drug with a narrow therapeutic
index (e.g., thiopurine methyl-transferase and 6-
mercaptopurine), or the lack of a therapeutic
effect where metabolic activation is required (e.g.,
cytochrome P450 2D6 and codeine). Likewise,
studies have shown that variations in target recep-
tors can lead to a lack of beneficial effects of a
drug, for example by increased desensitization
(e.g., beta-2 adrenoreceptor and albuterol).
Another mechanism impacting drug efﬁcacy
is altered binding kinetics (e.g., serotonin 1B
receptors and fluoxetine). Recent studies have
shown that genetic variants can be linked to the
susceptibility and progression of disease as well as
to a response to a drug treatment (e.g., choles-
terol ester transfer protein, atherosclerosis, and
statins; or apolipoprotein E, Alzheimer’s disease,
and tacrine). There are multiple genetic mecha-
nisms, including alterations in transcript stabil-
ity, splice sites, or promotor binding regions, all
of which can alter expression levels. The impact
of these changes on functional protein levels such
as reduced amounts or stability, or compromised
enzymatic function, requires further study.
Furthermore, how this fits into protein-protein
interactions (e.g., coupling to second messengers)
and biological pathways (e.g., redundant, com-
peting, or complementary routes of clearance or
signaling) needs to be understood in order to
predict clinical consequences.
With advances in genomic technology, large-
scale accumulation of information on drug path-
ways (sometimes called pharmacogenomics) is
possible. These profiling studies can be DNA-
based, transcript-based, or protein-based. Both
pharmacogenetics and pharmacogenomics stud-
ies are of interest under this solicitation. It is
essential to completely understand the signifi-
cance of genetic variation at the molecular level,
and the implications of the diverse genetic con-
texts present in different human populations.
The incidence of SNPs (singly and in combina-
tions of haplotypes) and gene duplication or
deletion events must be interpreted correctly to
associate genetic variation with the prediction of
drug effects, and this may require development
of new analytical tools. Population-based studies
that examine the interactions between genetic
predisposition for disease and the genetic factors
determining medication responses are also of
interest for this initiative.
Ultimately, both a mechanistic understanding
and robust statistical validation of putative phar-
macogenetics effects are sought, and the transla-
tion to clinical impact is highly desirable. The goal
of the ﬁeld is to be able to predict the effects of a
medication in an individual based upon his/her
genome, but much research must be performed
before that is possible in a comprehensive manner.
Accurate descriptions of drug response phenotypes
are challenging and difﬁcult, and further research
is required to define these phenotypes. The
Pharmacogenetics Research Network is intended
to address this need to acquire basic research
results and store the information in a knowledge
base, which will lead to a more complete under-
standing of drug actions, clinical translation of the
information, and future drug development. 
The Pharmacogenetics Research Network
will continue to be comprised of a series of mul-
tidisciplinary research and database groups, each
of which is performing state-of-the-art studies in
pharmacogenetics, either independently or in
conjunction with other network groups.
While pursuing the highest quality research
studies, each network group must agree to meet
the following expectations: 1) to further develop
the knowledge base, PharmGKB, which is a
database with accurate and detailed deﬁnitions of
pharmacogenetic phenotypes linked to geno-
types; 2) to advance the research ﬁeld, by deﬁn-
ing common goals and needs, and contributing
to solving problems of the field through discus-
sions and workshops; 3) to produce and share
resources, such as biological reagents, and experi-
mental and computational tools, to be dissemi-
nated rapidly and with minimal restrictions; and
4) to communicate with scientists both within
and outside the network, and to foster transla-
tion and application of this knowledge. These
requirements are further detailed below, and are
included in the speciﬁc review criteria.
A research group should be organized
around a unifying theme, for example, a family
of proteins with which drugs interact, a set of
drug pathways leading to the site of action, or
drug treatments for a particular disease. The
group should be comprised of a multidisciplinary
team of investigators, minimally including per-
sonnel with backgrounds in cellular/molecular
pharmacology, genetics/genomics, and clinical
expertise. Individuals from the ﬁelds of pharma-
cology, pharmaceutics, physiology, genetics,
genomics, clinical medicine, medicinal chem-
istry, epidemiology, statistics, bioinformatics,
and computational biology may be incorporated
and must demonstrate that they can work
together. This research team should propose cur-
rent, cutting-edge pharmacogenetics studies.
They should be “driven by the science” to pro-
duce the highest quality research results for depo-
sition into PharmGKB and for publication. The
research groups will be responsible for serving as
interactive resources for the developers of
PharmGKB in their self-described areas.
Applications should not simply be proposed
as a series of projects from all investigators work-
ing in pharmacogenetics at an institution.
Careful thought should be given to the deﬁnition
of a research group’s goals, and the steps to be
taken to accomplish those goals. The best core or
project teams to accomplish the research goals
should be assembled; applications that cross mul-
tiple institutions are acceptable. An application
should discuss how existing databases were used
to design and approach the solution of a pharma-
cogenetic problem, and how PharmGKB can
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group must justify their choice of a research area
as the most appropriate, demonstrate their study
design and power, and employ state-of-the-art
technical approaches, including statistics and
analyses. The selected research problem in phar-
macogenetics could be conceived starting with
the identiﬁcation of all possible variants (a geno-
type-to-phenotype approach) or beginning with
well-characterized patient materials (a pheno-
type-to-genotype approach). The applicant
group should state the advantages and disadvan-
tages of the approach chosen, and where conver-
gence is expected with other studies ongoing in
the ﬁeld.
Correct and complete descriptions of pheno-
types and association with genotypes form the
core organizing principle underlying the
Pharmacogenetics Research Network. The
research groups being funded are required to pro-
duce meaningful data sets suitable to populate
PharmGKB. Scientiﬁcally valid research questions
should be constructed to yield data that con-
tribute to advancing the understanding in the
ﬁeld, and that are appropriate for deposition into
the knowledge base. The types of data deposits
that are expected should be described in detail,
along with the time frame for their submission.
Both human and animal data, as well as non-
mammalian systems, will be accepted. Where ani-
mals or cell lines or model organisms are being
examined, they should be justiﬁed as the appro-
priate reference models, consistent with the goal
of identifying and interpreting human genetic
drug response variants.
Research groups should address how the
pharmacogenetic researchers outside of the net-
work can be positively impacted. Useful sample
sets should be offered to established reposito-
ries (e.g., the National Institute of General
Medical Sciences [NIGMS] Human Genetic
Cell Repository at the Coriell Institute, http://
locus.umdnj.edu/nigms/) for immortalization
and distribution. Useful reagents (e.g., anti-
bodies, primers) should be made easily avail-
able. Software tools should be shared freely
whenever possible. 
Current papers representative of the research
field being studied should be deposited by the
research groups into the community submissions
project in PharmGKB. Evidence of these steps
taken will attest to the desire of the research
group to serve in a scientific network and to
share their findings with the scientific commu-
nity, and should be presented in the application.
A database group applying to continue
PharmGKB should present a plan to further
develop the knowledge base as a research resource
that will store, organize, present, and integrate
pharmacogenetic knowledge. PharmGKB must
display a variety of data types: genetic variants,
haplotypes, population frequencies, summary sta-
tistics, oligonucleotide and cDNA microarray
data, molecular and functional screening assays,
pharmacokinetic data, pharmacodynamic data,
and, where appropriate, clinical data demonstrat-
ing the consequences of genetic variation. It
should have in place user-friendly methods to
accept these data deposits of diverse forms and
sizes. In all cases, the data should be described
using the standard nomenclature of the respective
ﬁelds. The knowledge base should have reciprocal
links to other established databases, such as
GenBank, dbSNP, PDB, etc.
The knowledge base should describe
gene-protein-drug-disease relationships, with
each object layer completely represented.
Relationships between these different data types
should be displayed visually, and reﬂect the opin-
ions and agreement of researchers working in
these ﬁelds. Raw data should be stored wherever
possible, so that PharmGKB can be mined to
learn of new correlations. This is intended to be
a hypothesis-generating tool. Moreover, data
should also be summarized and interpreted so
that the information in the knowledge base is
accessible to all scientist-users. Given the long
history of the field of pharmacogenetics, there
should be a current and complete literature
archive linked to complete publications wherever
possible. Existing high value data sets outside of
the network research groups should be sought to
populate PharmGKB, to ensure complete and
even-handed representation across the field of
pharmacogenetics. Methods to establish credit
and provide practical scientiﬁc incentives for sub-
mitters should be proposed. 
Applications to continue the knowledge Base
PharmGKB should reflect the current status of
the project, and describe how the design aspects,
implementation, and maintenance will be contin-
ued or improved upon. Careful attention should
be paid to issues of curation, and delineating who
has the responsibility to format, abstract, and
check the different kinds of data sets for com-
pleteness and accuracy. Comparisons should be
made to other successful ongoing database efforts.
Future major design directions should be pre-
sented and discussed, with prototypes. Discussion
of accomplishments, challenges, and obstacles
should be provided, and/or external observations
and alternative strategies on how to overcome
problem areas. There should be evidence of the
practical ability to work with the research groups
in the network. If a new database group is
funded, copies of the existing datasets and data
tables will be provided at the time of award,
according to the prior negotiated terms and con-
ditions regarding future portability. 
Taken together, the research and database
groups of the Pharmacogenetics Research Network
and Knowledge Base should encompass a range of
ongoing studies and original data on pharmacolog-
ically important genes, proteins, and pathways.
This will be accomplished by funding a balanced
series of research groups that are studying different
gene families, drug treatments, and diseases of sig-
nificance to human health. The scope of the
Pharmacogenetics Research Network will likely
continue to include enzymes of drug metabolism,
small molecule transporters, and target receptors
and pathways involved in drug treatment of car-
diovascular diseases, asthma, cancer, and depres-
sion, and may broaden somewhat in reﬂection of
the participating NIH institutes’ interests.
This network will be continued as a trans-
NIH effort; the institutes’ specific interests:
NIGMS is interested in studies identifying
robust, statistically valid correlations between
pharmacogenetic responses (phenotypes) and
genetic variation (genotypes, haplotypes) using
state-of-the-art approaches and technologies, and
in the deposition of this knowledge into a data-
base designed to be accessible by the entire
research community.
The National Cancer Institute (NCI) is
interested in projects that can potentially lead to
meaningful improvements in clinical and survival
endpoints, and in studies of genetic variability in
human populations that may influence risk of
preneoplastic conditions or primary and sec-
ondary malignancies after exposure to medica-
tions, including cancer therapies.
The National Heart, Lung, and Blood
Institute (NHLBI) is interested in studies of the
role of genetic polymorphisms and their func-
tional consequences in modulating treatment
responses in heart, lung, blood, and sleep diseases.
The National Human Genome Research
Institute (NHGRI) supports research on how
databases represent phenotypes, particularly
related to genetic variation, and encourages the
use and extension of standardized ontologies, as
well as rapid data release. 
The National Institute on Drug Abuse
(NIDA) is interested in the influence of genetic
variation on metabolic, homeostatic, neurocogni-
tive, and physiological responses to abused drugs,
as well as the safety and efﬁcacy of drugs used for
the treatment of addiction, dependence, and
withdrawal, and in drug-drug interactions (e.g.,
antiretrovirals and drugs of abuse).
The National Institute of Environmental
Health Sciences (NIEHS) is interested in identi-
fying the response genes that are important to
understanding genetic susceptibility to environ-
mental exposures (see the Environmental
Genome Project at http://www.niehs.nih.gov/
envgenom/home.htm). 
The National Library of Medicine (NLM) is
interested in knowledge representation and the
design and management of databases with med-
ical data.
The Ofﬁce of Research on Women’s Health
(ORWH) is interested in evaluating the
importance of gender differences in genetic poly-
morphisms of proteins important in the pharma-
cokinetics and pharmacodynamics of drugs and
drug reactions, and the role of hormones and
other factors. 
This RFA will use the NIH U01 award
mechanism. The applicant is solely responsible
for planning, directing, and executing the pro-
posed project. The RFA is a one-time solicita-
tion. The anticipated award date is on or after 1
July 2005. Applications that are not funded in
the competition described in this RFA may be
resubmitted as NEW investigator-initiated appli-
cations using the standard receipt dates for NEW
applications described in the instructions to the
PHS 398 application.
This RFA uses just-in-time concepts. It uses
the nonmodular budgeting formats. Follow the
instructions for nonmodular budget research
grant applications and submit the detailed cate-
gorical budget information on the PHS 398
form. This program does not require cost sharing
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Statement at http://grants.nih.gov/grants/policy/
nihgps_2001/part_i_1.htm.
The NIH U01 is a cooperative agreement
award mechanism. In the cooperative agreement
mechanism, the Principal Investigator retains the
primary responsibility and dominant role for plan-
ning, directing, and executing the proposed pro-
ject, with NIH staff being substantially involved as
a partner with the Principal Investigator as
described under the section “Cooperative
Agreement Terms and Conditions of Award.”
NIH makes no commitment to continue the
cooperative agreement programs beyond the ini-
tially awarded period of performance. 
Attendance at two Steering Committee
meetings per year is required. These will likely
rotate between the East and West coasts and cen-
tral United States. Travel funds should be
requested for this purpose for the Principal
Investigator and for one to two other Observers.
A plan for depositing data into PharmGKB is
required. See the current submission methods at
http://www.pharmgkb.org/submit/index.jsp.
This satisﬁes the NIH requirement for shar-
ing research data for applications greater than
$500,000 direct costs in any year of the proposed
research. Funds should be requested to support
individuals capable of submitting data to
PharmGKB.
A letter should be included in the applica-
tion, stating that the applicant research group
members have read all of the existing policies of
the Pharmacogenetics Research Network
(http://pharmgkb.org/home/policies/index.jsp).
The letter should indicate that the group mem-
bers will adhere to each of the policies and will
contribute to the development of future policies
that will guide the network’s actions. 
Applications must be prepared using the
PHS 398 research grant application instructions
and forms (rev. 5/2001). Applications must have
a DUN and Bradstreet (D&B) Data Universal
Numbering System (DUNS) number as the
Universal Identifier when applying for federal
grants or cooperative agreements. The DUNS
number can be obtained by calling (866) 705-
5711 or through the web site at http://www.
dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of
the PHS 398 form. The PHS 398 document is
available at http://grants.nih.gov/grants/fund-
ing/phs398/phs398.html in an interactive for-
mat. For further assistance contact GrantsInfo,
301-435-0714, e-mail: GrantsInfo@nih.gov. 
Using the RFA label: The RFA label available
in the PHS 398 (rev. 5/2001) application form
must be afﬁxed to the bottom of the face page of
the application. Type the RFA number on the
label. Failure to use this label could result in
delayed processing of the application such that it
may not reach the review committee in time for
review. In addition, the RFA title and number
must be typed on line 2 of the face page of the
application form and the YES box must be
marked. The RFA label is also available at: http://
grants.nih.gov/grants/funding/phs398/labels.pdf.
The Center for Scientiﬁc Review (CSR) will
not accept any application in response to this
RFA that is essentially the same as one currently
pending initial review, unless the applicant with-
draws the pending application. However, when a
previously unfunded application, originally sub-
mitted as an investigator-initiated application, is
to be submitted in response to an RFA, it is to be
prepared as a NEW application. That is, the
application for the RFA must not include an
Introduction describing the changes and
improvements made, and the text must not be
marked to indicate the changes from the previ-
ous unfunded version of the application. 
Letters of intent must be received by 19 July
2004. Applications are due 19 August 2004. The
earliest anticipated start date is 1 July 2005.
Contact: Rochelle M. Long, Pharmacology,
Physiology, and Biological Chemistry Division,
NIGMS, NIH, Bldg 45, Rm 2AS.49G, MSC
6200, Bethesda, MD 20892-6200 USA, 301-
594-1926, fax: 301-480-2802, e-mail: longr@
nigms.nih.gov; Richard A. Anderson, Genetics
and Developmental Biology Division, NIGMS,
NIH, Bldg 45, Rm 2AS.25B, MSC 6200,
Bethesda, MD 20892-6200 USA, 301-594-
0943, fax: 301-480-2228, e-mail: andersor@
nigms.nih.gov; Ken Kobayashi, Cancer Therapy
Evaluation Program, NCI, NIH, 6130 Exec-
utive Blvd, Ste 7131, MSC 7426, Rockville,
MD 20852-4907 USA, 301-496-1196, fax:
301-402-0428; e-mail: kobayashik@ctep.nci.
nih.gov; J. Fernando Arena, Division of Cancer
Control and Population Sciences, NCI, NIH,
6130 Executive Blvd, Executive Plz N, MSC
7395, Rm 5104, Rockville, MD 20852-4907
USA, 301-594-5868, fax: 301-402-4279, e-mail:
arenaj@mail.nih.gov; Susan Banks-Schlegel,
Division of Lung Diseases, NHLBI, NIH,
Rockledge Two, Rm 10220, 6701 Rockledge
Dr, MSC 7952, Bethesda, MD 20992-0001
USA, 301-435-0202, fax: 301-480-3557, e-mail:
schleges@nih.gov; Dina Paltoo, Division of
Heart and Vascular Diseases, NHLBI, NIH,
Rockledge Two, Rm 9180, 6701 Rockledge Dr,
MSC 7940, Bethesda, MD 20892-0001 USA,
301-435-1802, fax: 301-480-1336, e-mail: 
paltood@mail.nih.gov; Lisa D. Brooks, Genetic
Variation Program, NHGRI, NIH, 31 Center
Dr, Rm B2B07, Bethesda, MD 20892-2033
USA, 301-435-5544, fax: 301-480-2770, e-mail:
lisa_brooks@nih.gov; Joni L. Rutter, Division of
Neuroscience and Behavioral Research, NIDA,
NIH, 6001 Executive Blvd, Rm 5227, MSC
9555, Bethesda, MD 20892-9555 USA, 301-
435-0298, fax: 301-594-6043, e-mail: jrutter@
mail.nih.gov; Kimberly Gray, Division of
Extramural Research and Training, NIEHS,
NIH, 111 T.W. Alexander Drive, PO Box
12233, MD EC-21, Research Triangle Park, NC
27709 USA, 919-541-0293, fax: 919-316-4606,
e-mail: kg89o@nih.gov; Milton Corn, Extra-
mural Programs, NLM, NIH, 6705 Rockledge
Dr, Bldg 1, Ste 301, Bethesda, MD 20892-0001
USA, 301-496-4621, fax: 301-402-2952, e-mail:
cornm@mail.nlm.nih.gov; Lisa Begg, Research
Programs, ORWH, OD, NIH, One Center Dr,
Rm 201, MSC 0161, Bethesda, MD 20892-
0001 USA, 301-496-7853, fax: 301-402-1798,
e-mail: beggl@od.nih.gov.
Reference: RFA No. RFA-GM-04-002
Strategic Partnering to Evaluate Cancer
Signatures
The purpose of this initiative is to build on recent
demonstrations that molecular signatures correlate
with important clinical parameters in cancer. The
National Cancer Institute (NCI) invites investiga-
tors to form strategic partnerships that will bring
together the multi-disciplinary expertise and
resources needed to determine how the information
derived from comprehensive molecular analyses can
be used to improve patient care and ultimately,
patient outcomes. Applicants are asked to propose
evaluation of potential clinical usefulness of molec-
ular signatures already developed using a variety of
molecular analysis technologies including DNA,
RNA or protein-based technologies.
Molecular signatures have been able, in ret-
rospective studies, to identify subgroups of
patients whose tumors are histopathologically the
same but who have different clinical outcomes.
The challenge is to translate the information in
these molecular signatures into tools that can be
used in clinical decision-making. To meet this
challenge, signatures must be conﬁrmed in inde-
pendent studies. Critical elements of signatures
that correlate most strongly with the clinical end-
point of interest must be identified and con-
firmed. Robust assays feasible for use in the
clinical setting must be developed and validated.
This iterative process of signature reﬁnement and
confirmation and assay refinement requires
diverse scientific expertise and access to signifi-
cant patient and tissue resources.
This initiative is an open competition that
will provide the cancer research community the
opportunity to establish collaborations focused
on the translation of promising molecular pro-
ﬁles toward clinical application.
NCI will continue the policy of requiring
public release in a timely fashion of the rich data
sets generated during these projects. Access to
these data sets will benefit the entire cancer
research community. This initiative will help
ensure that the NCI goal of eliminating the suf-
fering and death from cancer by 2015 is met. 
The projects funded by this RFA are intended
to exploit the successes of the many research pro-
jects applying comprehensive molecular analysis in
cancer. Comprehensive molecular technologies
have been demonstrated to provide a snapshot of
the biological state of a tumor. The ability of mol-
ecular proﬁles to provide useful clinical informa-
tion is now being demonstrated in many projects
throughout the cancer research community and
needs to be evaluated further. Projects are discov-
ering molecular signatures by analysis of gene
expression at the RNA level, gene expression fol-
lowing protein translation, gene mutations, DNA
deletions, DNA ampliﬁcations, epigenetic changes
of DNA and post-translational modification of
proteins. The challenge is to move beyond the ini-
tial discovery of potentially useful profiles, to
decide what subset of the elements in the proﬁles
needs to be measured, to conﬁrm that the proﬁles
are robust and can be reproducibly measured and
to evaluate the clinical utility of the proﬁles. 
This RFA is open to all interested, qualiﬁed
investigators. The initiative is intended to sup-
port projects carrying out the extensive research
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molecular proﬁles and their integration into clin-
ical decision-making. Applicants should propose
projects that address clinical issues or needs in a
specific cancer or a closely related set of cancers
or in a group of patients whose cancers have
related molecular alterations. Collaborations
must be established to provide all of the expertise
and clinical resources required to achieve pro-
posed project goals. It is anticipated that these
will be multi-institutional projects involving
investigators with expertise in technology devel-
opment and application, cancer biology, oncol-
ogy, pathology, clinical cancer research,
biostatistics, bioinformatics and, possibly, bio-
medical imaging.
Applicants must propose projects that build
on previously identified molecular profiles.
Applications proposing only proﬁle discovery or
technology development projects will not be
considered responsive to this RFA. The proposed
studies should be designed to conﬁrm and reﬁne
signatures that have been demonstrated to pro-
vide information that is potentially useful clini-
cally and that may be used to aid in making
clinical decisions. Applicants may propose to
define critical components in the signature, to
confirm that the selected components continue
to provide the desired clinical information and to
develop robust assays for measuring those com-
ponents. They may continue to develop and/or
modify analytical technologies and algorithms for
data analysis required to meet the goals of the
proposed projects. 
Applicants must establish the collaborations
necessary to bring together the expertise needed
for the project. Successful completion of the pro-
ject will require expertise in analytical technolo-
gies, cancer biology, oncology, pathology, clinical
cancer research, biostatistics, bioinformatics and
possibly biomedical imaging.
Applicants must describe the clinical ques-
tion(s) or need(s) they plan to address. The clin-
ical questions posed should address a
well-defined clinical need in one or a closely
related set of tumors or in a group of patients
whose cancers have related molecular alterations.
Examples of questions of interest may include,
but are not limited to: risk of progression in
early stage disease; prognosis at the time of diag-
nosis; identification of subsets within a tumor
stage or grade where there is known heterogene-
ity in clinical behavior including differential
response to standard therapies and/or radiation
response; and selection of appropriate patients
for or prediction of response to selected or tar-
geted therapies. Applicants to this initiative
should not propose projects addressing early
detection of cancer in asymptomatic or high-risk
populations or risk of progression of pre-malig-
nant lesions. 
Applicants may propose the use of a variety
of analytical platforms(s). Applicants may pro-
pose to evaluate signatures the have previously
been identiﬁed using analytical technologies such
as, but not limited to, gene expression microar-
rays, SAGE, multiplex PCR or any of a large
number of protein analysis technologies.
Genomic analysis technologies such as array
CGH, comprehensive mutational analysis tech-
nologies, SNP analysis and analysis of epigenetic
events are also appropriate. Applicants must
demonstrate that they have experience with the
analytical technologies that will be used in the
project and demonstrate that the technologies
can be used for analysis of standard pathological
specimens. Applicants are encouraged, but not
required, to propose the use of multiple analyti-
cal strategies. For example, projects may be pro-
posed to analyze gene expression in both frozen
tissue and paraffin-embedded tissue, to analyze
gene expression at both the RNA and protein
level or to analyze both epigenetic alterations and
gene expression. The integration of data to build
clinically useful profiles that can be measured
reproducibly in a clinical setting must be the
focus of the project, no matter which technolo-
gies or analytic platforms are proposed.
Applicants must justify the numbers of spec-
imens to be analyzed based on appropriate statis-
tical designs for the proposed studies. Applicants
must have established collaborations to ensure
availability of the clinical materials required. The
availability of tissue resources with appropriate
clinical annotation is critical to the successful
completion of the projects. Experience has
demonstrated that the dimensionality of the mol-
ecular proﬁling data requires the analysis of hun-
dreds, not tens, of specimens to get statistically
significant results. Applicants may propose to
obtain tissues from a previous collection or
prospectively, as long as the specific aims pro-
posed can be accomplished within the period of
the grant award. Demonstrated access to the req-
uisite tissues will be critical to the successful
review of the application. It is recognized that
tissue needs may change as the projects are car-
ried out. NCI staff will work with investigators
to help identify additional tissue resources needed
to meet project goals.
Applicants should request sufficient
resources to ensure that they will be able to col-
lect, manage and analyze the data generated.
Applicants must address issues related to obtain-
ing, managing and controlling the quality of the
clinical data needed for specimen annotation.
Continued development of strategies to more
effectively address issues of data management
and analysis will be an inter-project cooperative
activity of the funded projects.
Applicants should request sufficient
resources for their bioinformatics staff to be able
to provide an appropriate interface with the NCI
Center for Bioinformatics (NCICB). Sharing of
the data between projects where appropriate and
public release of data after publication will be a
requirement for this initiative. Gene expression
data will be shared through the NCICB Gene
Expression Database using the Gene Expression
Data Portal and database. Proteomics data and
other types of data can be shared through the
NCICB site as the capabilities of the site are
expanded. They may also be shared through
investigators’websites or on other publicly avail-
able websites.
The conﬁrmation, reﬁnement and evaluation
of clinically useful molecular profiles and the
development of robust clinical assays are the
primary goals of this initiative. Clinical utility of
the signatures and performance of the clinical
assays in the context of their intended clinical use
must be validated before they can be integrated
into clinical practice. Final validation of the pro-
ﬁles in a clinical trial setting is beyond the scope of
this initiative. However, it is anticipated that some
of the projects may be ready to move proﬁles into
clinical trials as early as the midpoint of the pro-
ject period. NCI staff will facilitate collaborations
between the projects funded on this initiative and
other clinical resources and clinical trials activities
supported by NCI including: the clinical coopera-
tive groups; the Program for the Assessment of
Clinical Cancer Tests (PACCT); the SPORE pro-
grams and the NCI Cancer Centers.
This RFA will use the Natiional Institutes of
Health (NIH) cooperative agreement (U01)
award mechanism. As an applicant you will be
solely responsible for planning, directing, and
executing the proposed project. This RFA is a
one-time solicitation. The anticipated award date
is 1 April 2005. Applications that are not funded
in the competition described in this RFA may be
resubmitted as NEW investigator-initiated appli-
cations using the standard receipt dates for NEW
applications described in the instructions to the
PHS 398 application.
This RFA uses just-in-time concepts. It also
uses the non-modular budgeting formats. Follow
the instructions for non-modular budget research
grant applications. This program does not require
cost sharing as deﬁned in the current NIH Grants
Policy Statement at http://grants.nih.gov/grants/
policy/nihgps_2001/part_i_1.htm. 
The NIH (U01) is a cooperative agreement
award mechanism. In the cooperative agreement
mechanism, the Principal Investigator retains the
primary responsibility and dominant role for
planning, directing, and executing the proposed
project, with NIH staff being substantially
involved as a partner with the Principal
Investigator, as described under the section
“Cooperative Agreement Terms and Conditions
of Award.” At this time, it is not known if this
RFA will be reissued.
In order to ensure maximum progress in the
projects funded by this initiative and to maxi-
mize progress toward the NCI 2015 goals, sev-
eral special activities will be required of the
funded investigators. An annual meeting of all
funded investigators will be held to share
progress and research insights that may beneﬁt all
of the projects. 
The annual scientific meeting will be initi-
ated after the ﬁrst year of funding. One or more
other focused meetings will be held each year to
address arising issues or to take advantage of spe-
cial scientific opportunities. Applicants should
request travel funds in their budgets for key per-
sonnel to attend two meetings per year.
The funded investigators will be asked to
work together on issues common to all funded
projects. Although each applicant will propose an
independent project, all applicants are expected
to face many of the same challenges and will ben-
eﬁt from the experiences of and interactions with
the other funded investigators. The interactions
of the funded groups will be overseen by a
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tors, the PI and one additional investigator, from
each funded project and appropriate NCI staff
members. A Steering Committee organizing
meeting will be held shortly after funding is initi-
ated. The Steering Committee will focus on
common problems and issues, especially issues of
data management and analysis. Applicants
should state in their applications their commit-
ment to participating on the Steering Committee
and in interactions among the funded groups.
When proposed studies involve collection of
human samples, specimens and/or clinical data,
investigators should consider the issues raised and
guidance provided in the NIH Brochure entitled
“Research on Human Specimens: Are You
Conducting Research Using Human Subjects?”
(http://www-cdp.ims.nci.nih.gov/policy.html) and
in the OHRP Guidance on Repositories, Tissue
Storage Activities and Data Banks (http://ohrp.
osophs.dhhs.gov/g-topicstest.htm) to ensure
appropriate protection of human subjects in
research.
Applicants must describe how they intend to
meet the NIH policies for sharing of data or why
data sharing is not possible. In this regard, atten-
tion is drawn to the NIH Final Statement on
Sharing Research Data (http://grants.nih.gov/
grants/policy/data_sharing/index.htm and http://
grants.nih.gov/grants/guide/notice-files/
NOT-OD-03-032.html), which was published in
the NIH Guide on 26 February 2003 (“Data
Sharing Guidelines”). This is an extension of NIH
policy on sharing research resources, and reafﬁrms
NIH support for the concept of data sharing. The
new policy becomes effective with the 1 October
2003 receipt date for applications or proposals to
NIH. Investigators submitting an NIH applica-
tion will be required to include a plan for data
sharing or to state why data sharing is not possi-
ble. The statement required by this section should
be prepared with reference to the provision below
for Awardee Rights and Responsibilities within
Terms and Conditions of Award. 
Intellectual property (IP) issues continue to
provide challenges to the establishment of com-
plex, collaborative projects. This issue is being
addressed and managed in different ways by
many different projects supported by NCI. The
policy of the NIH is to make available to the
public the results and accomplishments of the
activities that it funds. NIH recognizes that cer-
tain research activities may result in inventions
and that grantees are entitled to protect such
inventions through patenting and licensing activi-
ties in accordance with the Bayh-Dole Act, 35
USC § 200 et seq. and the implementing regula-
tions, 37 CFR Part 401 (“Bayh-Dole Act”). To
address the interest in assuring that research
resources are accessible, NCI requires applicants
who respond to this RFA to submit a plan (1) for
sharing the unique research resources generated
through the grant; and (2) addressing how they
will exercise IP rights, should any be generated
through this grant, while making such research
resources available to the broader scientiﬁc com-
munity. The sharing of research resources and
IP plans must make unique research resources
readily available for research purposes to qualiﬁed
individuals within the scientific community in
accordance with the NIH Grants Policy
Statement (http://grants.nih.gov/grants/policy/
nihgps_2001/) and the Principles and Guidelines
for Recipients of NIH Research Grants and
Contracts on Obtaining and Disseminating
Biomedical Research Resources: Final Notice,
December 1999 (http://ott.od.nih.gov/
NewPages/RTguide_final.html and http://
ott.od.nih.gov/NewPages/64FR72090.pdf)
(“NIH Research Tools Guidelines”). These docu-
ments also define terms, parties, responsibilities,
prescribe the order of disposition of rights, pre-
scribe a chronology of reporting requirements,
and delineate the basis for and extent of govern-
ment actions to retain rights. Patent rights clauses
may be found at 37 CFR Part 401.14 and are
accessible from the Interagency Edison webpage
(http://www.iedison.gov/). 
If applicant investigators plan to collaborate
with third parties, the research tools sharing plan
must explain how such collaborations will not
restrict their ability to share research materials pro-
duced with NIH funding. All applicants will be
expected to have addressed IP issues with their
proposed collaborators before submitting their
applications and to have documented the status of
their arrangements by providing a copy of a signed
agreement, a signed Memorandum of Under-
standing between collaborating institutions or a
letter of collaboration countersigned by all rele-
vant parties that describes the IP issues and pro-
vides applicants with all rights necessary to
perform activities required by the research plans.
Successful applicants are expected to have resolved
any outstanding IP issues before funding is
awarded. It is anticipated that successful applicants
may subcontract with third party for proﬁt institu-
tions to perform certain aspects of the research
plans described in their applications. Successful
applicants will be expected to ensure that they
obtain sufficient rights in such subcontracts to
enable them to meet their obligations under the
NIH Research Tools Guidelines and the Data
Sharing Guidelines, both of which are extensions
of the distribution of unique research resources
policy contained in the NIH Grants Policy
Statement (page 11-62). In drafting these subcon-
tracts, grantees will want to give some thought to
the relative rights and responsibilities of the par-
ties, particularly with respect to the dissemination
and use of raw data, results and analyses.
The NCI Technology Transfer Branch staff
works with NCI funded investigators on IP issues
and has developed strategies for sharing IP. Staff
of the NCI Technology Transfer Branch will pro-
vide their expertise as needed to the investigators
funded under this initiative and their technology
transfer and grants and contracts administration
ofﬁces. Addressing IP issues will be a component
of the review of the projects. 
As discussed earlier, grantees will be required
to publicly release data to the cancer research
community through the NCI Center for
Bioinformatics web site or through other appro-
priate public websites. Applicants should commit
to the public release of data and request funds in
their budgets to support bioinformatics staff
interactions with the NCICB staff.
Applications must be prepared using the
PHS 398 research grant application instructions
and forms (rev. 5/2001). Applications must
have a DUN and Bradstreet (D&B) Data
Universal Numbering System (DUNS) number
as the Universal Identifier when applying for
federal grants or cooperative agreements. The
DUNS number can be obtained by calling
(866) 705-5711 or through the web site at
http://www.dunandbradstreet.com/. The
DUNS number should be entered on line 11 of
the face page of the PHS 398 form. The PHS
398 document is available at http://grants.
nih.gov/grants/funding/phs398/phs398.html in
an interactive format. For further assistance
contact GrantsInfo, 301-435-0714, e-mail:
GrantsInfo@nih.gov.
Using the RFA label: The RFA label avail-
able in the PHS 398 (rev. 5/2001) application
form must be affixed to the bottom of the face
page of the application. Type the RFA number
on the label. Failure to use this label could result
in delayed processing of the application such that
it may not reach the review committee in time
for review. In addition, the RFA title and num-
ber must be typed on line 2 of the face page of
the application form and the YES box must be
marked. The RFA label is also available at:
http://grants.nih.gov/grants/funding/phs398/
labels.pdf. 
Applications hand-delivered by individuals to
the NCI will no longer be accepted. This policy
does not apply to courier deliveries (i.e. FEDEX,
UPS, DHL, etc.) See http://grants.nih.gov/
grants/guide/notice-files/NOT-CA-02-002.html
for more information. This policy is similar to and
consistent with the policy for applications
addressed to the Center for Scientific Review
(CSR) as published in the NIH Guide Notice at
http://grants.nih.gov/grants/guide/
notice-ﬁles/NOT-OD-02-012.html.
The CSR will not accept any application in
response to this RFA that is essentially the same
as one currently pending initial review, unless
the applicant withdraws the pending applica-
tion. However, when a previously unfunded
application, originally submitted as an investi-
gator-initiated application, is to be submitted in
response to an RFA, it is to be prepared as a
NEW application. That is the application for
the RFA must not include an Introduction
describing the changes and improvements
made, and the text must not be marked to indi-
cate the changes from the previous unfunded
version of the application.
Letters of intent must be received by 22 June
2004. Applications are due 22 July 2004. The
earliest anticipated start date is 1 April 2005.
Contact: James W. Jacobson, Division of
Cancer Treatment and Diagnosis, NCI, 6130
Executive Blvd, EPN Rm 6035A, Bethesda,
MD 20892-0001 USA, 301-402-4185, fax:
301-402-7819, e-mail: jacobsoj@mail.nih.gov;
Tracy Lugo, Division of Cancer Treatment and
Diagnosis, NCI, 6130 Executive Blvd, EPN
Rm 6035A, Bethesda, MD 20892 USA, 301-
496-1591, fax: 301-402-7819, e-mail: lugot@
mail.nih.gov.
Reference: RFA No. RFA-CA-04-015
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